This is explainable by the fact that CD38, the type II transmembrane glycoprotein to which the mAb binds, is expressed on plasma cells, plasmablasts, and immature transitional B cells, and are highly present on malignant myeloma cells [18]. The gene discussed is CD38; the disease is plasma cell myeloma.